Core Insights - The approval of the botulinum toxin product by Aimeike enhances the company's aesthetic medicine product line, filling a gap in its offerings [1] - The combination of this new product with existing offerings allows the company to provide more comprehensive solutions to customers, thereby strengthening its core competitiveness [1] - The aesthetic medicine consumption penetration rate still has significant room for growth, indicating potential for future expansion [1] Product Development - Aimeike has several products in development, including those for weight management and submental fat, which will further enrich its aesthetic medicine product pipeline upon launch [1] - The company is investing in self-research to create new product lines while also pursuing external acquisitions to enhance its product offerings [1] Financial Projections - The forecast for the company's net profit attributable to shareholders for 2025-2027 is set at 1.564 billion, 1.794 billion, and 2.099 billion yuan, respectively [1] - Corresponding price-to-earnings ratios (PE) are projected to be 28.2, 24.6, and 21 times for the same period [1] - The company maintains an "outperform the market" rating based on these projections [1]

文/新浪财经上海站 途景 近日，网传截图显示，国信证券计算机行业首席分析师熊莉的朋友圈称：我已经哑了，谢绝一切路演 了。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 有用户在社交平台评论：AI太火了！卖方分析师路演讲到失声．．．卖方分析师直接宣布进入"静音模 式"。 责任编辑：公司观察 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 途景 近日，网传截图显示，国信证券计算机行业首席分析师熊莉的朋友圈称：我已经哑了，谢绝一切路演 了。 有用户在社交平台评论：AI太火了！卖方分析师路演讲到失声．．．卖方分析师直接宣布进入"静音模 式"。 责任编辑：公司观察 ...

Core Viewpoint - Guosen Securities initiates coverage on Zijin Gold International (02259) with an "outperform" rating, highlighting the company's inherited competitive advantages from Zijin Mining in the mining sector, focusing on overseas gold resources, low-cost acquisitions, and technological empowerment for strong future growth [1] Group 1: Company Overview - Zijin Gold International is formed by integrating Zijin Mining's overseas gold mines, becoming a leading global gold mining company [1] - The company holds rights to nine gold mines in resource-rich areas including Central Asia, South America, Oceania, and Africa, successfully establishing a leading position in the global gold mining industry through tailored operational models and continuous resource development [1] Group 2: Resource and Production Growth - As of the end of 2024, the company's gold reserves are approximately 856 tons, ranking ninth globally, with expertise in developing low-grade and difficult-to-process gold resources [2] - The company anticipates an average annual compound growth rate of 21.4% in gold production from 2022 to 2024, driven by acquisitions of new mines and technological upgrades of existing ones [2] - Projections indicate that from 2025 to 2027, the average annual compound growth rate in gold production could exceed 15%, maintaining rapid growth momentum [2] Group 3: Expansion Projects - The company has planned a series of construction and expansion projects within existing mining areas to enhance production capacity and resource conversion [3] - Specific projects include optimizing processing techniques at the Tajikistan Jilau/Talco mine, accelerating key projects at the Australian Norton Goldfield, and increasing processing capacities at various mines in Guyana, Colombia, Suriname, and Ghana [3] Group 4: Market Outlook - The long-term outlook remains positive, with expectations of a sustained bull market for gold, driven by anticipated interest rate cuts by the Federal Reserve and ongoing global economic factors that could further elevate gold prices [4]

Core Viewpoint - Guosen Securities initiates coverage on Zijin Gold International (02259) with an "outperform" rating, highlighting the company's competitive advantages inherited from Zijin Mining in the mining sector, focusing on overseas gold resources, low-cost acquisitions, and technological empowerment for strong future growth [1] Group 1: Company Overview - Zijin Gold International is formed by integrating Zijin Mining's overseas gold mines, becoming a leading global gold mining company [1] - The company holds interests in nine gold mines located in resource-rich areas across Central Asia, South America, Oceania, and Africa, including significant projects in Tajikistan, Kyrgyzstan, Australia, Guyana, Colombia, Suriname, Ghana, Kazakhstan, and Papua New Guinea [1] Group 2: Growth Potential - As of the end of 2024, the company's gold reserves are approximately 856 tons, ranking ninth globally, with a focus on developing low-grade and difficult-to-process gold resources [2] - The company anticipates an average annual compound growth rate of 21.4% in gold production from 2022 to 2024, driven by acquisitions of new mines and technological upgrades of existing ones [2] - For the period from 2025 to 2027, the company expects a continued average annual compound growth rate of over 15% in gold production [2] Group 3: Project Developments - The company has planned a series of construction and expansion projects within existing mining areas to enhance production capacity and resource conversion [3] - Specific projects include ongoing development of low-grade ore processing technologies at the Tajikistan mine, upgrades to the Norton Goldfield in Australia to increase annual processing capacity from 9 million tons to 11 million tons, and various enhancements at other mines to significantly boost production capabilities [3] Group 4: Market Outlook - The long-term outlook for gold prices remains positive, with a projected cumulative increase of over 65% by 2025, marking the best performance since 1979 [4] - Factors supporting this outlook include anticipated interest rate cuts by the Federal Reserve in 2026, a decline in dollar credibility, and continued accumulation of gold by global central banks, which may further drive up gold prices [4]

Group 1 - The company announced the suspension of large-scale subscriptions, conversions, and regular investment for the Jianxin Hengjiu Value Mixed Securities Investment Fund starting from January 13, 2026, with a limit of 10 million yuan per account per day [1][37] - Other business operations will continue as usual during the suspension period, and the large-scale subscription and investment services will resume on January 15, 2026 [1][37] - Investors can contact the company's customer service for inquiries or visit the official website for more information [1][37] Group 2 - The Jianxin Technology Smart Selection Stock Fund is open for regular subscription, redemption, conversion, and regular investment as of January 12, 2026 [4] - The fund management company is responsible for managing and operating the fund assets, with the custodian being GuoXin Securities Co., Ltd. [4] - Investors are encouraged to check their transaction application confirmation status through sales outlets or the company's customer service [4][5]

截至2026年1月9日收盘，国信证券(002736)报收于13.45元，上涨0.6%，换手率0.38%，成交量36.06万 手，成交额4.85亿元。 当日关注点 交易信息汇总资金流向 1月9日主力资金净流入743.93万元；游资资金净流入195.38万元；散户资金净流出939.31万元。 公司公告汇总关于延长国信证券股份有限公司2026年面向专业投资者公开发行短期公司债券（第一期） 簿记建档时间的公告 国信证券股份有限公司2026年面向专业投资者公开发行短期公司债券（第一期）原定簿记建档时间为 2026年1月9日15:00至18:00。因当日市场变化较为剧烈，经全体簿记参与人协商一致，簿记建档结束时 间延长至2026年1月9日19:00。 国信证券股份有限公司2026年面向专业投资者公开发行短期公司债券（第一期）票面利率公告 国信证券股份有限公司2026年面向专业投资者公开发行短期公司债券（第一期）已获证监会注册同意， 发行规模不超过30亿元，期限为365天。2026年1月9日完成簿记询价，利率区间为1.30%-2.30%，最终确 定票面利率为1.70%。发行人将于2026年1月12日及13日面向专业机构投资 ...

Group 1 - The core viewpoint of the report is that Guosen Securities has given a "better than market" rating to Yingke Medical (300677.SZ) due to its leading position in the global disposable glove market and its diversified business layout with significant global advantages [1] - Yingke Medical's competitive edge is attributed to its multi-dimensional cost barriers and global operational capabilities, which are essential in the disposable glove industry [1] - The report highlights that the supply-demand dynamics in the disposable glove industry are continuously improving as market disruptions are clearing [1]

Group 1 - The core viewpoint of the article is that Guosen Securities has given a "better than market" rating to Aimeike (300896.SZ) based on recent developments in its product pipeline and market potential [1] - Aimeike's exclusive distribution of Huons BioPharma's injectable botulinum toxin product has received regulatory approval for sale in China, including Hong Kong and Macau, filling a gap in its product line [1] - The company is expected to enhance its core competitiveness by offering comprehensive solutions through the combination of new and existing products, with ongoing research and development in weight management and submental fat products [1] Group 2 - The medical aesthetics consumption penetration rate still has significant room for improvement, indicating potential growth opportunities for the industry [1] - Aimeike is investing in self-research to develop new product lines while also pursuing mergers and acquisitions to enrich its product pipeline and expand international business [1] - The company’s performance growth is supported by these strategies, although there are potential risks related to project progress and market competition [1]

Group 1 - The report highlights that all four active quantitative strategies outperformed the equity mixed fund index this week, with absolute returns of 4.86% for the Excellent Fund Performance Enhancement Portfolio, 5.13% for the Exceeding Expectations Selected Portfolio, 5.39% for the Brokerage Golden Stock Performance Enhancement Portfolio, and 5.98% for the Growth and Stability Portfolio [1][2][17] - Year-to-date, the Excellent Fund Performance Enhancement Portfolio ranks in the 42.03 percentile among active equity funds, while the Exceeding Expectations Selected Portfolio ranks in the 38.48 percentile, the Brokerage Golden Stock Performance Enhancement Portfolio ranks in the 35.18 percentile, and the Growth and Stability Portfolio ranks in the 28.46 percentile [1][2][17] Group 2 - The Excellent Fund Performance Enhancement Portfolio is constructed by benchmarking against active equity funds rather than broad indices, utilizing quantitative methods to enhance performance based on the holdings of top-performing funds [3][18] - The Exceeding Expectations Selected Portfolio is built by screening stocks based on exceeding expectations events and analyst profit upgrades, focusing on both fundamental and technical criteria to select stocks that show strong support [4][25] - The Brokerage Golden Stock Performance Enhancement Portfolio uses a stock pool from brokerage recommendations, optimizing the combination to minimize deviation from the stock pool while aiming to outperform the equity mixed fund index [5][33] - The Growth and Stability Portfolio employs a two-dimensional evaluation system for growth stocks, prioritizing stocks closer to their earnings report dates and using multi-factor scoring to select high-quality stocks [6][40] Group 3 - The report provides performance statistics for each strategy, indicating that the Excellent Fund Performance Enhancement Portfolio achieved an annualized return of 21.40% from 2012 to 2025, outperforming the equity mixed fund index by 9.85% [55] - The Exceeding Expectations Selected Portfolio recorded an annualized return of 35.09% from 2010 to 2025, exceeding the equity mixed fund index by 23.98% [60] - The Brokerage Golden Stock Performance Enhancement Portfolio achieved an annualized return of 21.71% from 2018 to 2025, outperforming the equity mixed fund index by 14.18% [65] - The Growth and Stability Portfolio achieved an annualized return of 40.56% from 2012 to 2025, exceeding the equity mixed fund index by 26.33% [70]

Core Viewpoint - The report tracks the performance of various active quantitative strategies by GuoXin JinGong, aiming to outperform the median returns of actively managed equity funds, with a focus on four specific strategies: Excellent Fund Performance Enhancement, Unexpected Selection, Broker Golden Stock Performance Enhancement, and Steady Growth Combination [2][3]. Group 1: Performance Overview - The Excellent Fund Performance Enhancement strategy achieved an absolute return of 4.86% this week, with a relative excess return of 0.06% compared to the mixed equity fund index [3][13]. - The Unexpected Selection strategy recorded an absolute return of 5.13% this week, with a relative excess return of 0.34% [3][24]. - The Broker Golden Stock Performance Enhancement strategy had an absolute return of 5.39% this week, with a relative excess return of 0.60% [3][34]. - The Steady Growth Combination strategy achieved an absolute return of 5.98% this week, with a relative excess return of 1.19% [3][43]. - Year-to-date, the Excellent Fund Performance Enhancement strategy ranks in the 42.03 percentile among active equity funds, while the Unexpected Selection ranks in the 38.48 percentile, Broker Golden Stock in the 35.18 percentile, and Steady Growth in the 28.46 percentile [3][13][24][34][43]. Group 2: Strategy Details - The Excellent Fund Performance Enhancement strategy benchmarks against the median returns of actively managed equity funds, utilizing a quantitative approach to enhance performance based on the holdings of top-performing funds [8][49]. - The Unexpected Selection strategy focuses on selecting stocks that show both fundamental support and technical resonance, aiming to build a portfolio of stocks with unexpected performance [18][53]. - The Broker Golden Stock Performance Enhancement strategy uses a stock pool from broker recommendations, optimizing the selection to control deviations from the overall market performance [26][58]. - The Steady Growth Combination strategy employs a two-dimensional evaluation system for growth stocks, prioritizing those with upcoming earnings announcements to capture potential excess returns [35][64].